Moexipril

Moexipril
Clinical data
Trade names	Univasc
AHFS/Drugs.com	Monograph
MedlinePlus	a695018
Routes of; administration	Oral
ATC code	C09AA13 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	13-22%
Protein binding	90%
Metabolism	Hepatic (active metabolite, moexiprilat)
Elimination half-life	1 hour; 2-9 hours (active metabolite)
Excretion	50% (faeces), 13% (urine)
Identifiers
	IUPAC name (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;
CAS Number	103775-10-6 ;
PubChem CID	91270;
IUPHAR/BPS	6571;
DrugBank	DB00691 ;
ChemSpider	82418 ;
UNII	WT87C52TJZ;
KEGG	D08225 ;
ChEMBL	ChEMBL1165 ;
CompTox Dashboard (EPA)	DTXSID9023330 ;
Chemical and physical data
Formula	C27H34N2O7
Molar mass	498.576 g·mol−1
	(what is this?) (verify)

Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor)^[1] used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics.^[2]

It works by inhibiting the conversion of angiotensin I to angiotensin II.^[3]

It was patented in 1980 and approved for medical use in 1995.^[4] Moexipril is available from Schwarz Pharma under the trade name Univasc.^[3]^[5]

^ Hochadel, Maryanne, ed. (2006). The AARP Guide to Pills. Sterling Publishing Company. p. 640. ISBN 978-1-4027-1740-6. Retrieved 2009-10-09.
^ Belal F, Metwaly FH, Younes KM, Amer SM (2009). "Development of Membrane Electrodes for the Specific Determination of Moexipril Hydrochloride in Dosage Forms and Biological Fluids". Portugaliae Electrochimica Acta. 27 (4): 463–475. doi:10.4152/pea.200904463.
^ ^a ^b Rodgers K, Vinson MC, Davis MW (1996). Breakthroughs: New drug approvals of 1995 -- part 1 (Report). Vol. 140. Advanstar Communications, Inc. p. 84.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495.
^ Banerji S (2004). "Angiotensin-Converting Enzyme Inhibitors". In Dart RC (ed.). Medical toxicology. Lippincott Williams & Wilkins. p. 647. ISBN 978-0-7817-2845-4. Retrieved 2009-10-09.

[1] Hochadel, Maryanne, ed. (2006). The AARP Guide to Pills. Sterling Publishing Company. p. 640. ISBN 978-1-4027-1740-6. Retrieved 2009-10-09.

[development-2] Belal F, Metwaly FH, Younes KM, Amer SM (2009). "Development of Membrane Electrodes for the Specific Determination of Moexipril Hydrochloride in Dosage Forms and Biological Fluids". Portugaliae Electrochimica Acta. 27 (4): 463–475. doi:10.4152/pea.200904463.

[newdrug-3] Rodgers K, Vinson MC, Davis MW (1996). Breakthroughs: New drug approvals of 1995 -- part 1 (Report). Vol. 140. Advanstar Communications, Inc. p. 84.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495.

[5] Banerji S (2004). "Angiotensin-Converting Enzyme Inhibitors". In Dart RC (ed.). Medical toxicology. Lippincott Williams & Wilkins. p. 647. ISBN 978-0-7817-2845-4. Retrieved 2009-10-09.

[1]

[2]

[3]

[4]

[5]